- Pharmaceutical Executive Brings Scientific and Commercial Experience to
Nabi Biopharmaceuticals' Board -
BOCA RATON, Fla., Aug. 22 /PRNewswire-FirstCall/ -- Nabi
Biopharmaceuticals (Nasdaq: NABI) announced today that it has elected Leslie
Hudson, Ph.D., to its board of directors. Dr. Hudson is currently president
and chief executive officer of DOV Pharmaceutical, Inc., and has served in
several senior management positions, including vice president of discovery
research at Glaxo Wellcome, group vice president and general manager at
Phamacia Corp. and executive vice president and chief operating officer at
Repligen Corp. With the addition of Dr. Hudson, Nabi Biopharmaceuticals'
board now totals eight members.
"Les brings a broad research background and commercial experience in
Europe and the United States that will be a tremendous asset to our board of
directors and company," stated Thomas H. McLain, chairman, chief executive
officer and president, Nabi Biopharmaceuticals. "For more than 30 years, Les
has held a number of strategically important positions within the
biotechnology and pharmaceutical industries and in academia. We will benefit
from his expertise and experience in discovery research, product development
and commercialization at this significant point in Nabi Biopharmaceuticals'
strategic transformation."
Prior to DOV Pharmaceuticals, Dr. Hudson served as vice provost for
Strategic Initiatives at the University of Pennsylvania, where he facilitated
corporate partnerships and was responsible for technology transfer and
commercialization, corporate research and development collaborations and
regional economic development. Prior to this position, he served in several
positions at Pharmacia, including senior vice president of research and
exploratory development, and senior vice president of emerging technology and
commercial development. He was also general manager and group vice president
of ophthalmology, where he was responsible for the company's $1 billion
ophthalmology business including the launches of Xalatan, XalEase, Tecnis and
Xalacom. Dr. Hudson also worked at Glaxo in several senior research positions
including head of cancer, metabolic and hyperproliferative disease and vice
president for discovery research, in which he headed the company's genomics
program.
In addition to these corporate positions, Dr. Hudson has also worked in
academia. He was a visiting scientist in the department of cell biology at
Harvard University and head of the Department of Immunology at St. George's
Hospital Medical School in London, where he taught for 12 years.
Dr. Hudson received his Ph.D. in immunology from the Imperial College and
Middlesex Hospital Medical School at the University of London and his B.A. in
zoology from the Imperial College of Science, Technology and Medicine at the
University of London. He is also an associate of the Royal College of Science
and has published more than 80 papers, books and articles on immunology,
cancer and cell biology.
About Nabi Biopharmaceuticals
Nabi Biopharmaceuticals leverages its experience and knowledge in powering
the immune system to develop and market products that fight serious medical
conditions. We are poised to capture large, commercial opportunities in our
core business areas: Gram-positive bacterial infections, hepatitis, and kidney
disease (nephrology), and opportunistically in nicotine addiction. We have
three products on the market today: PhosLo(R) (calcium acetate), Nabi-HB(R)
[Hepatitis B Immune Globulin (Human)], and Aloprim(TM) [Allopurinol sodium
(for injection)] and a number of products in various stages of clinical and
preclinical development. The company filed its Marketing Authorization
Application in Europe for its product candidate, StaphVAX(R) [Staphylococcus
aureus Polysaccharide Conjugate Vaccine], in December 2004. The application
was accepted for review in January 2005. StaphVAX is currently in a
confirmatory Phase III clinical trial in the United States. StaphVAX is
designed to prevent the most dangerous and prevalent strains of S. aureus
bacterial infections. S. aureus bacteria are a major cause of hospital-
acquired infections and are becoming increasingly resistant to antibiotics.
The company's other products in development include Altastaph(TM)
[Staphylococcus aureus Immune Globulin Intravenous (Human)], an antibody for
prevention and treatment of S. aureus infections, NicVAX(TM) [Nicotine
Conjugate Vaccine], a vaccine to treat nicotine addiction, and Civacir(TM)
[Hepatitis C Immune Globulin (Human)], an antibody for preventing hepatitis C
virus re-infection in liver transplant patients. For additional information
on Nabi Biopharmaceuticals, please visit our website at: http://www.nabi.com .
This press release contains forward-looking statements that reflect the
company's current expectations regarding future events. Any such forward-
looking statements are not guarantees of future performance and involve
significant risks and uncertainties. Actual results may differ significantly
from those in the forward-looking statements as a result of any number of
factors, including, but not limited to, risks relating to the possibility that
our confirmatory Phase III clinical trial for StaphVAX or our plans to
commercialize StaphVAX in the European Union and United States may not be
successful; the possibility that we may not realize the value of our
acquisition of PhosLo; the company's ability to raise additional capital on
acceptable terms; the company's dependence upon third parties to manufacture
its products; the company's ability to utilize the full capacity of its
manufacturing facility; the impact on sales of Nabi-HB from patient treatment
protocols and the number of liver transplants performed in HBV-positive
patients; reliance on a small number of customers; the future sales growth
prospects for the company's biopharmaceutical products; and the company's
ability to obtain regulatory approval for its products in the United States or
abroad or to successfully develop, manufacture and market its products. These
factors are more fully discussed in the company's Annual Report on Form 10-K
for the fiscal year ended December 25, 2004 filed with the Securities and
Exchange Commission.
SOURCE Nabi Biopharmaceuticals
 back to top
Related links:
http://www.nabi.com
CONTACT:
Constance C. Bienfait, Vice President,
Investor Relations, Nabi, +1-561-989-5800
|
